Under the European Union’s Horizon Europe program, the EIC offered $14.7million to Pixelgen Technologies to expand the applications of its Pixelgen Proxiome Kit. This year, the kit was launched at the first kit and software for protein interactome analysis of single cells at high capacity.
Pixelgen’s mission is to deliver biology at high resolution by gaining in-depth insights into the molecular basis of cellular function. The kit aims to decipher the protein interactions of single cells in unprecedented ways. The kit is based on the company’s proprietary Proximity Network Assay, which delivers nanoscale spatial analysis of immune cell proteins at scale.
The expansion aims to include cell-to-cell interaction studies and formalin-fixed, paraffin-embedded (FFPE) tissue analysis, thus reinforcing its role in advancing drug discovery and precision medicine.
Simon Fredriksson, CEO and Co-founder of Pixelgen, said: “The process was rigorous, and the award further reinforces the value of Pixelgen's technology to increase our understanding of complex cellular and functional cell surface arrangements, which we believe will advance drug development and deepen our understanding of precision medicine.”
Fredriksson added that the overall response from the wider scientific community of leading researchers in industry and academia to the Proxiome Kit was positive.
